Quadrature Capital Ltd, Stifel Financial Corp, and other financial entities have acquired significant numbers of shares in Laboratory Corporation of America Holdings (Labcorp) (NYSE:LH), indicating increasing investor confidence. Multiple acquisitions reflect Labcorps expansion, notably purchasing selected assets from Invitae and BioReference Health's Diagnostics Business. Labcorp’s successful diagnostics sector saw it raise its earnings per share (EPS) midpoint guidance. Labcorp's acquisition strategy also led it to purchase bankruptcy-stricken genetic test maker Invitae for $239 million. Labcorp's earnings call transcripts for Q1, Q2, Q3 2024, and Q4 2023 indicate robust growth, despite EPS missing expectations in Q3 2024 and Full Year 2023. Labcorp stock shares reached a 52-week high twice in 2024, reflecting positive financial performance. It's also expected that the CEO's compensation package will be reviewed. A strategic SWOT insight of Labcorp has been decoded, hinting at business strengths and weaknesses. Lastly, Labcorp expanded its strategic alliances while finalizing the spin-off of Fortrea.
Laboratory Corporation of America Holdings LH News Analytics from Fri, 24 Apr 2020 07:00:00 GMT to Sat, 07 Dec 2024 10:48:33 GMT -
Rating 7
